Wearable devices like smartwatches, fitness trackers, and adhesive patches are revolutionizing how researchers test new medications, moving beyond traditional clinic visits to capture real-world health data continuously. A comprehensive analysis of over 1,000 clinical trials registered between 2001 and 2025 reveals that wearables are now being deployed across five major application areas in drug development, fundamentally changing how scientists measure whether treatments actually work. How Are Wearables Being Used in Clinical Trials? Researchers are integrating wearable-derived data into study protocols in five distinct ways. These applications span from measuring direct drug effects to optimizing dosing schedules and ensuring patients take their medications as prescribed. The flexibility of wearables allows researchers to monitor participants in their everyday environments rather than requiring frequent trips to medical offices, which improves both the quality of data and patient participation rates. - Drug Effects Measurement: Wearables capture how medications actually perform in real-world conditions by continuously monitoring physiological responses like heart rate, sleep patterns, and movement. - Dosing Optimization: Devices help researchers determine the most effective dose by tracking how different dosage levels affect patients over time without requiring constant clinic visits. - Medication Adherence: Wearables provide objective data on whether patients are taking their medications consistently, addressing one of the biggest challenges in clinical research. - Delivery Medium Optimization: Researchers use wearables to test different ways of delivering drugs, such as pills versus patches, by measuring how each method affects the body. - Delivery Technique Optimization: Devices help refine how medications are administered by monitoring real-time physiological responses to different application methods. What Types of Wearables Are Dominating Clinical Trials? Adhesive patches have emerged as the leading wearable technology in clinical trials, largely driven by the widespread use of continuous glucose monitoring devices for diabetes research. These small, skin-adhering sensors represent a major shift in how researchers collect health data. Beyond glucose monitoring, the range of physiological domains being tracked through wearables continues to expand significantly. Modern wearable patches now monitor sleep quality, cardiovascular function including heart rate and rhythm, motor activity and movement patterns, and even brain signals. This expanding coverage means researchers can simultaneously track multiple aspects of how a drug affects the body, providing a much more complete picture than traditional methods that relied on patient visits and blood tests. The continuous nature of wearable monitoring also captures variations throughout the day and night that would be impossible to detect through periodic clinic measurements. Why Does Regulatory Approval of Wearable Data Matter? Despite the rapid growth in wearable deployment across clinical trials, formal regulatory qualification of wearable-derived measures remains extremely rare. The U.S. Food and Drug Administration (FDA) has formally qualified only one wearable-based measure to date: the SV95C measurement used in Duchenne muscular dystrophy trials. This single qualification represents a significant milestone, but it also highlights a major gap in the field. Without FDA qualification, many wearable measurements cannot be used as primary endpoints in trials submitted to the agency for drug approval. This regulatory bottleneck creates a challenge for the field. Researchers can use wearables to gather rich, continuous data, but they often cannot rely on that data as the main evidence of whether a drug works when seeking FDA approval. Addressing this gap requires collaboration between device manufacturers, researchers, and regulators to establish which wearable measurements are reliable, reproducible, and clinically meaningful enough to support drug approval decisions. What's Next for Wearable Technology in Drug Development? The future of wearables in clinical trials extends beyond current glucose monitoring and activity tracking. Emerging technologies promise to expand the types of health data researchers can capture directly from the skin and body. These next-generation wearables include biochemical sensing modalities that go beyond glucose to measure other important molecules, transdermal spectroscopy that analyzes skin composition non-invasively, and wearable ultrasound devices that could provide imaging data from a patch-like device. These innovations could enable researchers to monitor drug metabolism, immune responses, and tissue changes in ways that were previously impossible outside of a laboratory setting. As these technologies mature and gain regulatory clarity, wearables are likely to become standard components of clinical trial design rather than novel additions. The shift toward continuous, real-world monitoring represents a fundamental change in how medical science tests whether new treatments actually help patients in their daily lives, moving beyond the artificial environment of clinic visits toward data collection that reflects genuine human experience.
